Literature DB >> 20014893

Guidance for the classification of carcinogens under the Globally Harmonised System of Classification and Labelling of Chemicals (GHS).

Douglas McGregor1, Alan Boobis, Marco Binaglia, Phil Botham, Laurence Hoffstadt, Sue Hubbard, Thomas Petry, Anthony Riley, Dirk Schwartz, Christa Hennes.   

Abstract

The United Nations Conference on Environment and Development (UNCED) has developed criteria for a globally harmonised system of classification and labelling of chemicals (GHS). With regard to carcinogenicity, GHS distinguishes between Category 1 ('known or presumed human carcinogens') and Category 2 ('suspected human carcinogens'). Category 1 carcinogens are divided into Category 1A ('known to have carcinogenic potential for humans'), based largely on human evidence, and 1B ('presumed to have carcinogenic potential for humans'), based largely on experimental animal data. Concerns have been raised that the criteria for applying these carcinogenicity classifications are not sufficiently well defined and potentially allow different conclusions to be drawn. The current document describes an attempt to reduce the potential for diverse conclusions resulting from the GHS classification system through the application of a series of questions during the evaluation of data from experiments with rodents; epidemiological data, which could lead to Category 1A, have not been considered. Answers to each question can lead either to a classification decision or to the next question, but this process should only be implemented in an environment of informed scientific opinion. The scheme is illustrated with five case studies. These questions are: (1) Has a relevant form of the substance been tested? (2) Is the study design relevant to human exposure? (3) Is there a substance-related response? (4) Is the target tissue exposure relevant to humans? (5) Can a mode of action be established? (6) Is the mode of action relevant to humans? (7) What is the potency?

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20014893     DOI: 10.3109/10408440903384717

Source DB:  PubMed          Journal:  Crit Rev Toxicol        ISSN: 1040-8444            Impact factor:   5.635


  6 in total

Review 1.  Case examples of an evaluation of the human relevance of the pyrethroids/pyrethrins-induced liver tumours in rodents based on the mode of action.

Authors:  Tomoya Yamada
Journal:  Toxicol Res (Camb)       Date:  2018-01-16       Impact factor: 3.524

Review 2.  Mode of action-based risk assessment of genotoxic carcinogens.

Authors:  Andrea Hartwig; Michael Arand; Bernd Epe; Sabine Guth; Gunnar Jahnke; Alfonso Lampen; Hans-Jörg Martus; Bernhard Monien; Ivonne M C M Rietjens; Simone Schmitz-Spanke; Gerlinde Schriever-Schwemmer; Pablo Steinberg; Gerhard Eisenbrand
Journal:  Arch Toxicol       Date:  2020-06-15       Impact factor: 5.153

Review 3.  The role of endogenous versus exogenous sources in the exposome of putative genotoxins and consequences for risk assessment.

Authors:  Ivonne M C M Rietjens; Arand Michael; Hermann M Bolt; Bourdoux Siméon; Hartwig Andrea; Hinrichsen Nils; Kalisch Christine; Mally Angela; Pellegrino Gloria; Ribera Daniel; Thatcher Natalie; Eisenbrand Gerhard
Journal:  Arch Toxicol       Date:  2022-03-06       Impact factor: 6.168

Review 4.  Glyphosate toxicity and carcinogenicity: a review of the scientific basis of the European Union assessment and its differences with IARC.

Authors:  Jose V Tarazona; Daniele Court-Marques; Manuela Tiramani; Hermine Reich; Rudolf Pfeil; Frederique Istace; Federica Crivellente
Journal:  Arch Toxicol       Date:  2017-04-03       Impact factor: 5.153

Review 5.  What is the meaning of 'A compound is carcinogenic'?

Authors:  Dieter Schrenk
Journal:  Toxicol Rep       Date:  2018-04-07

Review 6.  A proposal to improve clarity and communication in the EU Classification process for chemicals for carcinogenicity and reproductive and developmental toxicity.

Authors:  J E Doe
Journal:  J Appl Toxicol       Date:  2014-07-25       Impact factor: 3.446

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.